The Indian pharmaceutical sector remains a cornerstone of the national economy, serving as both a critical healthcare provider and a major export contributor.  The country supplying over 20% of global generic medicines and catering to more than 200 countries. The sector contributes approximately 2% to India’s GDP and employs over 2.9 million people, both directly and indirectly.

We, DART Analysts, based on data up to 2022, reported that the Indian Pharmaceutical industry had achieved an overall industry Compound Annual Growth Rate (CAGR) of 11.3%, with projections of 14% CAGR for the period 2023–2027. The earlier analysis highlighted robust growth potential driven by strong export performance, easing FDI norms, and high profitability across top-performing companies such as Sun Pharma, Alkem, and Zydus Lifesciences. However, the updated analysis (as of 2025) shows a moderation in growth momentum, with the industry CAGR averaging 8% over the period 2022–2025. This deceleration reflects pricing pressure in global generics, tighter regulatory oversight, and increased competition in key export markets, particularly the U.S. and Europe. Also, the previous projection was done in the light of the Covid -19 influence in the medical sector.

*Companies ranked based on FY2025 Revenue (highest – lowest)

The performance trend suggests that while the industry remains structurally sound, growth has transitioned from high double-digit expansion to a phase of consolidation. Companies are now focusing on portfolio diversification, complex generics, biosimilars, and specialty drugs to mitigate pricing pressures.  However, the recent tariff on the industry would adversely affect and compel manufacturers to move out of the country for export purpose.

Looking ahead, the Indian pharmaceutical sector is expected to stabilize and grow at a CAGR of around 7% between 2026 and 2029  lesser than the average growth of top players, supported by increasing domestic healthcare demand, production-linked incentives (PLI), capacity expansion under “Make in India,” and growing investments in R&D and digital health solutions.

This evolving trajectory underscores a strategic shift — from volume-led generics manufacturing toward value-led innovation, advanced formulations, and specialty segments, positioning India to sustain its global competitiveness in the coming decade.

Here is the detailed analysis of the Key Players of the Indian Pharmaceutical Sector:

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is India’s largest pharmaceutical company and one of the leading specialty generic companies globally. The company has a strong presence across multiple dosage forms such as injectables, tablets, ointments, sprays, creams, and liquids. Its diversified business spans branded and generic medicines, specialty products, over the counter (OTC) offerings, active pharmaceutical ingredients (APIs), and intermediates. Sun Pharma’s global footprint extends to over 100 countries, supported by world-class manufacturing facilities and a growing specialty portfolio that continues to strengthen its leadership in the pharmaceutical industry.

Cipla Ltd

Cipla Ltd is a globally recognized pharmaceutical company with a legacy of innovation and commitment to affordable healthcare. Established in 1935, Cipla has built a strong presence across India, Africa, North America, and other international markets. Its business is structured around three key areas APIs, respiratory care, and global access  catering to a broad range of therapeutic needs. With a wide product portfolio covering multiple therapeutic categories, Cipla continues to focus on patient-centric healthcare and advancing treatments for chronic and acute conditions.

Dr. Reddys Laboratories Ltd

Dr. Reddy’s Laboratories Ltd is an integrated global pharmaceutical company dedicated to providing affordable and innovative medicines for better health outcomes. The company operates across three core segments Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products offering a broad portfolio that includes generics, biosimilars, and differentiated formulations. With a strong presence in key markets across the world, Dr. Reddy’s focuses on therapeutic areas such as gastroenterology, cardiovascular, oncology, diabetes, pain management, and dermatology.

Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is one of India’s leading pharmaceutical companies, specializing in branded and generic formulations across multiple therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, diabetology, and pain management. The company has a strong domestic presence and a growing international footprint across regulated markets. Torrent Pharma continues to strengthen its research and development capabilities while pursuing strategic growth initiatives to expand its product portfolio and enhance its position as a trusted name in healthcare.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd, formerly known as Cadila Healthcare Limited, is a leading global life sciences company focused on delivering innovative healthcare solutions. With operations in more than 50 countries, Zydus is engaged in the discovery, development, and manufacturing of pharmaceuticals, biologics, and vaccines. The company has a strong pipeline in biosimilars and specialty medicines and operates multiple state-of-the-art manufacturing plants and research centers. Committed to science-driven innovation, Zydus continues to advance its mission of improving global health and patient well-being.

Industry Performance

The Indian pharmaceutical industry continues to be a major global player, ranked third in the world by volume and fourteenth by value. It is driven by its strength in generics, vaccines, and advanced formulations. During the pandemic, the industry demonstrated remarkable agility, quickly responding to global healthcare needs through rapid vaccine development, API supply, and distribution. Today, India is focusing on strengthening its self-reliance, consolidating its position in the global pharmaceutical landscape, and expanding into high-value segments such as biologics and specialty medicines. By embracing innovation, technology, and strategic growth, the industry aims to maintain its status as a resilient and globally competitive pharmaceutical powerhouse.

The performance of the key companies indicates that the Indian Pharma industry is growing at par with the global growth.  The reported margin of these key players was around 7.1% by taking into consideration the last 3 years’ data.  Details are as follows.

Industry Trends

India’s pharmaceutical sector continues to attract robust domestic and foreign investments, driven by government policy support, technological innovation, and global collaborations. Key developments reflect the nation’s push toward self-reliance, digital transformation, and high-value pharmaceutical manufacturing.  Some of the key drivers for further growth are:

• AI & Machine Learning Integration: Approximately 79% of pharmaceutical executives view AI and ML as critical drivers for innovation, enhancing drug discovery, manufacturing efficiency, and personalized medicine.
• Strategic Licensing Deals: Rani Therapeutics has entered a licensing agreement with Japan’s Chugai Pharmaceutical, potentially worth up to $1.09 billion, to develop oral antibody therapies.
• From the Government of India press-release “A Dose of Atmanirbhar Bharat” (April 13, 2025) – under the PLI Scheme for Bulk Drugs (KSMs/DIs/APIs): “While the initial commitment was ₹3,938.57 crore, the actual realized investment has already reached ₹4,253.92 crore (as of December 2024).
• From The Economic Times / IANS article (April 14, 2025): “FDI in India’s pharmaceuticals and medical devices sector has seen an inflow of ₹11,888 crore from April to December (FY2024-25), plus 13 FDI proposals worth ₹7,246.40 crore for brownfield projects, taking total FDI to ₹19,134.4 crore.
• PIB “INDIA: THE WORLD’S PHARMACY” (Aug 22, 2024) notes that India’s drug & pharmaceutical exports rose from US$15.07 billion in 2013–14 to US$27.85 billion in FY2023–24.
• Production Linked Incentive (PLI) Scheme for Pharmaceuticals: A scheme with an outlay of roughly ₹ 15,000 crore (for the pharma component) that supports manufacturing of high-value products (complex generics, biopharmaceuticals, patented drugs, etc.) from FY 2022-23 to FY 2027-28.
• PLI Scheme for Bulk Drugs (KSMs/DIs/APIs): With an outlay of around ₹ 6,940 crore, this is focused on manufacturing Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) to reduce import dependence.
• The adverse impacts of recent tariffs will have long term effect in industry growth. It would potentially disrupt pricing, supply chains, and international trade, and would lead companies to change their based country for export operations.

DART Consulting provides business consulting through its network of Independent Consultants.  Our services include preparing business plans, market research, and providing business advisory services. More details at https://www.dartconsulting.co.in/dart-consultants.html